home / stock / mllcf / mllcf short
Short Information | Molecular Partners AG (OTCMKTS:MLLCF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 7,083 |
Total Actual Volume | 12,032 |
Short Trends | |
---|---|
Cover Days | 4 |
Short Days | 16 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 354 |
Average Short Percentage | 76.37% |
Is there a MLLCF Short Squeeze or Breakout about to happen?
See the MLLCF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
03-01-2024 | $3.91 | $3.91 | $3.91 | $3.91 | 300 | 300 | 100% |
12-27-2023 | $4.13 | $4.13 | $4.13 | $4.13 | 100 | 100 | 100% |
06-05-2023 | $7.05 | $7.05 | $7.05 | $7.05 | 100 | 100 | 100% |
05-19-2023 | $7.09 | $7.09 | $7.09 | $7.09 | 100 | 100 | 100% |
05-05-2023 | $7.22 | $7.22 | $7.22 | $7.22 | 169 | 100 | 59.17% |
12-23-2022 | $6.18 | $6.18 | $6.18 | $6.18 | 557 | 500 | 89.77% |
08-24-2022 | $5.75 | $5.535 | $6 | $5.535 | 1,901 | 195 | 10.26% |
08-22-2022 | $6 | $6 | $6 | $6 | 350 | 300 | 85.71% |
08-18-2022 | $5.75 | $5.16 | $5.75 | $5.16 | 366 | 100 | 27.32% |
08-08-2022 | $6.05 | $6.05 | $6.05 | $6.05 | 293 | 293 | 100% |
07-01-2022 | $6.75 | $6.75 | $6.75 | $6.75 | 440 | 440 | 100% |
05-31-2022 | $6.71 | $6.71 | $6.71 | $6.71 | 100 | 100 | 100% |
04-26-2022 | $16.15 | $14.66 | $16.15 | $14.66 | 1,705 | 5 | 0.29% |
03-10-2022 | $25 | $25 | $25 | $25 | 1,600 | 1,600 | 100% |
02-28-2022 | $23 | $23 | $23 | $23 | 100 | 100 | 100% |
02-15-2022 | $25 | $26 | $26 | $25 | 850 | 100 | 11.76% |
02-01-2022 | $27.6 | $28.2 | $28.2 | $27.6 | 1,300 | 1,000 | 76.92% |
01-31-2022 | $27 | $27 | $27 | $27 | 350 | 350 | 100% |
01-24-2022 | $28.8 | $28.8 | $28.8 | $28.8 | 151 | 100 | 66.23% |
01-21-2022 | $29.25 | $29 | $29.25 | $29 | 1,200 | 1,200 | 100% |
News, Short Squeeze, Breakout and More Instantly...
Molecular Partners AG Company Name:
MLLCF Stock Symbol:
OTCMKTS Market:
Preclinical data of tetra-specific T cell engager MP0533 demonstrate preferential T cell mediated killing of AML cells, while sparing healthy cells Results highlight MP0533-mediated T-cell activation and tumor regression, as well as cytokine release in AML models without systemic advers...
ZURICH, Switzerland, April 19, 2024 (GLOBE NEWSWIRE) -- Today, Life Science Cares, a collective effort of the life science industry to reduce the impact of poverty and inequality in their communities, launched in Switzerland, marking its first expansion as an independent association into geograph...
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that all motions propos...